# Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension

> **NCT00257491** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 29 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmisartan
- **DRUG:** Telmisartan/HCTZ

## Key facts

- **NCT ID:** NCT00257491
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2013-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00257491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00257491, "Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00257491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*